Department of Medical Sciences and Public Health

Updated to June 2021

 

Ongoing job position: 

Associate Professor in Hematology at the Dipartimento di Scienze mediche e Sanità Pubblica, Università di Cagliari and Consultant at Ematologia-Centro Trapianti Midollo Osseo, Azienda Ospedaliera Brotzu, Ospedale Businco, Via Jenner s.n., 09124 Cagliari (Italy)

Number of Medical Council: Cagliari-8732

Academic titles

2021            National application (ASN 2018) for Full Professor in Hematology

2019            Chairman of Residency in Hematology of University of Cagliari

2018            Associate Professor in Hematology, Department of Medical Sciences and Public Health, University of Cagliari

2011            National application (ASN 2016) for Associate Professor in Hematology

2003            Degree in Psychology, Work and Organizations course, achieved at the Universit of Cagliari – 110 out of 110 summa cum laude –Thesis title “An humanization of hospital structures: the sterile room issue” (July, 3rd, 2003)

1997              Specialization in Haematology achieved at the University of Cagliari, Faculty of Medicine and Surgery with full marks and honours – Thesis title “HLA system and chronic HCV Hepatitis” – (December, 11th, 1997)

1992             Degree in Medicine and Surgery achieved at the University of Cagliari with full marks and honours – Thesis title: “Manometric oesophageal alterations in patients affected by Wilson disease” – (March, 20th, 1992)

1985              High School Diploma achieved at the Scientific High School “E. Fermi” (Nuoro) – 60 out of 60.

 

Educational activity at university and / or for institutions in Italy or abroad. 

2014-today    Teacher in the “Blood Diseases”,  Faculty of Medicine, University of Cagliari

2013-           Teacher in the “Blood Diseases”,  School of Specialization of Medical Genetics, University of Cagliari

2013-            Teacher in the PhD school “Environmental Science and Engineering and Innovation Science and Technology, University of Cagliari

2013-           Teacher in the “Blood Diseases”,  Biomedical Laboratory Degree , University of Cagliari

2012-           Teacher in the “Blood Diseases”,  School of Specialization in Oncology, University of Cagliari

2012-           Teacher in the “Blood Diseases”,  School of Specialization in Hematology, University of Cagliari

2011-           Teacher in the “Blood Diseases”,  School of Specialization in Clinical Pathology, University of Cagliari

2011-            Researcher for the Chair of Haematology of the Faculty of Medicine and Surgery of the University of Cagliari

2008            Haematology subject expert for the Faculty of Medicine and Surgery of the University of Cagliari in charge of auxiliary educational activity in Haematology courses.

2009            Tutoring international activity in the international cooperation project on bone marrow transplantation promoted by the I.M.E. (Mediterranean Institute of Hematology – Rome) and the Italian Foreign Ministry, provided to doctors coming from Kurdistan in the Bone Marrow Transplantation Centre of the Hospital Binaghi (Cagliari).

 

Training and research activities in Italian public organizations and abroad 

2013           Observer at the Leukemia Department, Anderson Cancer Center (Prof. Cortes MD), University of Texas, Houston, Texas (USA), 7-22 Sept 2013

2012           Full registration as Medical Practitioner at the General Medical Council of United Kingdom, 28/09/2012-28/09/2013

2012           Honorary Contract at the Department of Haematology, Hammersmith Hospital, Imperial College London (1 Oct-31 Dec 2012)

2010           Advanced course about Myelodysplasia in the Department of Leukemia, Anderson Cancer Center (Prof. Garcia-Manero MD), University of Texas, Houston, Texas (USA).

1996           Practical training course in Diagnostic with Ultrasounds in the Institute of Medical Clinic, Ultrasounds Diagnostic of the General University Hospital “A. Gemelli”, Faculty of Medicine and Surgery of the University Cattolica del Sacro Cuore, Rome.

1988           Visiting student in the Department of Pathology (Prof. Rao), University of Pittsburgh, School of Medicine, Pittsburg (Pennsylvania), USA.

 

I conducted the following clinical research according to GCP:

Projects carried out as Scientific Coordinator 

2018-           Scientific coordinator of the research project LR7/2017 Quality of life in Talassemia after transplantation: grant euro 110.000

2019-           Scientific coordinator of the research project Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative neoplasms (PROPHECY). A GIMEMA observational registry for Italian MPN patients, grant euro 300.000

2005-11    Scientific coordinator of the research project “Mathematical predictive models of reaction to bone marrow transplantation (Graft Versus Host Disease): the neural network”, carried out in cooperation with the Faculty of Engineering of the University of Cagliari.

2004-11    Scientific coordinator of the study “Bone marrow transplantation in a cohort of thalassemic patients coming from Middle East and developing countries: quality of life, communication and ethical issues. Paternalistic attitude and autonomy principle”, carried out in cooperation with the Institute San Raffaele of Milan.

2004-2010 Scientific coordinator of research topics in the field of the “Quality of Life in haematological patients” related to the communication of diagnosis, to the setting of the physician-patient relations and the quality of life in onco-haematological patients.

Projects carried out as Scientific Co-operator

2017-18        European Organization for Research and Treatment for Cancer (EORTC) e Department fur Psychiatrie, Psychoterapie und Psychosomatik Medizinishe Universitat Innsbruck sul progetto di ricerca: "Development of threshold for the EORTC QLQ C-30 and the EORT CAT measures to enable thei use for sympthom screening in daily clinical practice

2017-19        Dana-Farber Cancer Institute - Department of Medical Oncology, nel progetto di ricerca: "Validation of a Disease-Specific Measure for Quality of Life in Patients with the Myelodysplastic Syndrome (QUALMS)

 2017-19       European Organization for Research and Treatment for Cancer (EORTC) sul progetto di ricerca: "Patient reported outcomes in Chronic Myeloid Leukemia: development of questionnaire EORTC QLQ-CML-24

2015-19        European Organization for Research and Treatment for Cancer (EORTC) sul progetto di ricerca: "International development of four EORTC disease specific quality of life questionnaires for patients with Hodgkin lymphoma, high and low grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia

2013             Research staff member at Division 2. Fundamental Research Projects on specific areas of regional interest funded under the Regional Law Nr. 7/2007, Tender nr. 13, year 2013. Project title: “Quality of life at the end of life: a survey in the Sardinian territory”. Coordinator: Prof D’Aloja Ernesto, Department of Public Health, University of Cagliari. Total funding: €250,000

2012             Research staff member at Division 2, PRIN 2012. Project Title: “Are thyroid cancer and thyroid autoimmunity related? A clinical, molecular, immunological and cellular approach”. Principal Investigator: Prof. Stefano Mariotti, Department of Medical Sciences, University of Cagliari. Total funding €560,897

2012             Research staff member at Division 2. Fundamental or basic research projects for the promotion of scientific research and technological innovation in Sardinia, year 2012, funded under the Regional Law 7/2007. Research project Title: “NANOTOXSTAMOD”. Total funding: 300,000 Euros (132,940)

2007-11      Scientific co-operator in the biological and clinical research project “Genomic parameters related to the curative effect of the allogenic haematopoietic stem cell transplantation”, funded by the Fondazione Cariplo and carried out in cooperation with the Immunogenetics Centre of the Fondazione S. Raffaele del Monte Tabor of Milan. Research activity with Groups of National and International Cooperation for the treatment of Leukemias, Lymphomas, Myeloma and for the application of new transplantation protocols (GIMEMA, GITMO, EBMT).

 2007-11        Scientific co-operator in the regional research project LR 7/8/2007: “Study on the susceptibility to myelodysplasias in the population living in Sardinia through the genome wide analysis”, carried out in cooperation with the University of Sassari, Microsurgical Department, Haematology Unit.

 2005-07        Scientific co-operator in the biological and clinical research project “Transplantation from unrelated donor in thalassemic patients: study on the role of the polymorphism of the HLA-G gene and the genotype of the promoter IL10, in order to reduce the mortality risks related to transplantation and increase the pool of patients treatable with transplantation” funded by the IME (Mediterranean Institute of Haematology) Foundation of Rome and by the Foreign Ministry.

 2002-05        Scientific co-operator in the research and health education project “Study on the role of HLA non-classical antigens (HLA-G, E, F) and other genetic polymorphisms (KIR genes) involved in the immunitary response, in order to reduce mortality risks in unrelated donor transplantation in high-risk thalassemic patients” funded by the Assessorato alla Sanità della Regione Autonoma della Sardegna (12045/00 UPB S12.023).

Research activity in clinical and biological experimental protocols, approved by the Ethical Committee of the ASL 8 of Cagliari as Principal Investigator (PI):

2020            Studio osservazionale in pazienti con mastocitosi sistemica avanzata trattati con midostaurina in Italia – Studio OVIDIO”. Promotor/Sponsor: Novartis

2020            Caratteristiche cliniche e laboratoristiche della Policitemia Vera. Codice Protocollo: PV-ARC. Promotore/Sponsor: Unità Operativa di Ematologia-Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-Malpighi

2020-           Monitorare i sintomi riportati dai Pazienti con leucemia mieloide cronica per migliorare l’aderenza alla terapia e la risposta al trattamento: lo studio pilota EMPATHY”. Promotor/Sponsor: Northwestern University Feinberg School of Medicine

2019-           A phase II, single-arm, multicenter study of full treatmentfree remission in patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved a sustained deep molecular response for at least 1 year: DANTE study. Sponsor: NOVARTIS

2019            Studio osservazionale sul trattamento con Iclusig® (Ponatinib) di pazienti con Leucemia Mieloide Cronica (LMC) in Italia” INCB-ITMA-CML-401. Sponsor: INCYTE

2018-           An International Multi-Centric Observational Study on the Use of Ruxolitinib in the Treatment of Patients with Polycythemia Vera resistant or intolerant to hydroxyurea” CINC424BIC04. Sponsor: NOVARTIS

2018-           Prospective FLOW-cytometry Evaluation of circulating Residual leukemic Stem cells in Chronic Myeloid Leukemia patients during TKI treatment (prospective FLOWERS study). Valutazione prospettica citofluorimetrica delle cellule staminali leucemiche circolanti residue nei pazienti affetti da leucemia mieloide cronica in trattamento con inibitori delle tirosinochinasi(FLOWERS)-Codice identificativo: AIRC IG 20133. Sponsor: Università di Siena

2017            CML0916. An international field study for the reliability and validity of the Phase IV EORTC Quality of Life module for patients with Chronic Myeloid Leukemia (EORTC QLQ-CML24): Sponsor GIMEMAProtocol CML0916. An international field study for the reliability and validity of the Phase IV EORTC Quality of Life module for patients with Chronic Myeloid Leukemia (EORTC QLQ-CML24): Sponsor GIMEMA

2017            Protocol: An international field study for the reliability and validity of the Phase IV EORTC Quality of Life modules for patients with Hodgkin’s Lymphoma (EORTC QLQ-HL27), high-grade non-Hodgkin’s Lymphoma (EORTC QLQ-NHL-HG29), low-grade non-Hodgkin’s Lymphoma (EORTC QLQ-NHL-LG20), and Chronic Lymphocytic Leukaemia (EORTC QLQ-CLL17). Sponso: EORTC

2017            protocol: Development of thresholds for the EORTC QLQ-C30 and the EORTC CAT measures to enable their use for symptom screening in daily clinical practice. Sponsor: Medical Univesity of Innsbruck Depsrtment of Psychiatry, Psychotherapy and Psychosomatic

2016            Protocol: "Registro epidemiologico della LMC nella Regione Sardegna – Studio LMC-Res". Sponsor: Rete ematologica sarda - GIMEMA 

2014            Protocol CAMN107EIC01. Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia- and/or BCR-ABL positive CML in chronic phase". Sponsor: NOVARTIS, Basilea, Switzerland

2014            Protocol AMN107AIC05. A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID. Sponsor: Novartis

2015             Protocol “Prognostic significance and longitudinal assessment of patient-reported outcomes in myelodysplastic syndromes (PROMYS): PROMYS INTERNATIONAL REGISTRY”. Sponsor:GIMEMA

2014           Protocol QoL-CML0713. Mid to Long-term Quality of Life Effects Of imatiNIb versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS). Sponsor: GIMEMA

2014              Protocol AMN107AIC05. A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia-positive CML after two different durations of consolidation treatment with nilotinib 300mg BID. Sponsor: Novartis.

2014             Protocol Validation of a Myelodysplasia-Specific Measure of Quality of Life (QUALMS). Sponsor GIMEMA.

2013              Protocol CAMN107CIC03. An observational, open-label, multi-center, prospective follow-up study of patients with chronic phase CML treated with nilotinib in the ENEST1st study . Sponsor Novartis.

2011              Protocol Compassionate-INC424. INC 424 (Ruxolitinib) for compassionate use in patients with MF. Sponsor: Novartis

2011              Protocol Eqol-MDS-1. Eltrombopag for the treatment of thrombocytopenia due to low and intermediate risk myelodysplastic syndromes (EQol-MDS). Sponsor: Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria

2010              Protocol CC-5013-MDS-005. Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, study to compare the efficacy and safety of Lenalidomide (Revlimid®) versus placebo in subjects with transfusion-dependent anemia due to IPSS low or intermediate-1 risk Myelodysplastic Syndromes Without Deletion 5q[31] and unresponsive or refractory to erythropoiesis-stimulating agents. Sponsor: CELGENE, New Jersey, USA.

2010              Protocol CAMN107EIC01. Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia- and/or BCR-ABL positive CML in chronic phase. Sponsor: NOVARTIS, Basilea, Switzerland.

2010              Protocol GIMEMA QoL CML0310. Patient reported outcomes in chronic myeloid leukemia. Sponsor: Gruppo Italiano Malattie Ematologiche dell’Adulto.

2010              Protocol NIPMS-Celgene-MDS-ITA-002. Observational, non-interventional, multicentric study with a retrospective and prospective integration of the data of the Register 648/96 on the use of lenalidomide (Revlimid®) in anaemic transfusion-dependent patients affected by low or intermediate-1 risk Myelodysplastic Syndrome with a 5q deletion associated or not to other chromosomal abnormalities – “MOnitoraggio REvlimid” – “MORE Study”. Sponsor: CELGENE, New Jersey, USA

2009              Protocol GIMEMA MDS 0108. Prognostics significance and longitudinal assessment of patient-reported quality of life and symptoms in high-risk myelodysplastics syndromes. A large-scale international, observational study. Sponsor: Gruppo Italiano Malattie Ematologiche dell’Adulto.

Research activity in clinical and biological experimental protocols, approved by the Ethical Committee of the ASL 8 of Cagliari as Co-Investigator:

 2016           Protocol CML-1415 “Remissione sostenuta senza trattamento nella leucemia mieloide cronica BCR-ABL+: uno studio prospettico che confronta Nilotinib versus Imatinib con passaggio a Nilotinib in assenza di risposta ottimale”. Sponsor GIMEMA

2015            Protocol “Prognostic significance and longitudinal assessment of patient-reported outcomes in myelodysplastic syndromes (PROMYS): PROMYS INTERNATIONAL REGISTRY”. Sponsor:GIMEMA 

2013         Protocol CC-486-AML-001. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myelogenous Leukemia in Complete Remission. Sponsor Celgene

2012           Protocol CINC424A2401. An open-label, multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or postessential thrombocythemia myelofibrosis (PET-MF). Sponsor: Novartis

2012             Protocol Observational study of quality of life in Thalassemia patients underwent bone marrow transplantation. Sponsor: CTMO Ospedale Binaghi.

2011              Protocol MDS Aza?Transplant. A open label, phase 2, non randomized, multicentre trial to assess the feasibility of induction treatment with 5?Azacitidine (5?AZA) followed by allogeneic stem cell transplantation (allo?SCT) or continued 5?AZA treatment in patients without a suitable ?sibling or unrelated? stem cell donor with IPSS Int2/High risk myelodysplastic syndromes (MDS). Sponsor: Consorzio Mario Negri Sud (CMNS)

2010              Protocol GIMEMA LAL1509. A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive (Ph+) Acute Lymphoblastic Leukemia (ALL) patients. Sponsor: Gruppo Italiano Malattie Ematologiche dell’Adulto.

2008              Protocol GIMEMA APL 0406. Randomized phase III study to compare Arsenic Trioxide (ATO) combined with ATRA and chemotherapy with anthracycline (AIDA) to be used for newly diagnosed not high risk acute promyelocytic leukemias. Sponsor: Gruppo Italiano Malattie Ematologiche dell’Adulto.

2008              Protocol GIMEMA MDS 0306. Multicentric open study to evaluate the security, tolerability and effectiveness of Deferasirox (ICL 670) in patients affected by Myelodysplastic Syndrome with chronic transfusional Hemosiderosis. Sponsor: Gruppo Italiano Malattie Ematologiche dell’Adulto.

2007              Protocol GIMEMA LAL 1205. Multicentric phase II study on de novo treatment of Ph positive lymphoblastic acute leukemia with BMS-354825 protein kinase inhibitor. Sponsor: Gruppo Italiano Malattie Ematologiche dell’Adulto.

2007              Protocol GIMEMA LAL 0904. Prospective phase II study on the adult Lymphoblastic Acute Leukemia treatment: imatinib combined with chemotherapy in the treatment of Ph positive forms. Sponsor: Gruppo Italiano Malattie Ematologiche dell’Adulto.

2007              Protocol Allotreo Thalassemia. Clinical multicentric phase II study to evaluate the security and effectiveness of the Treosulfan drug in the preparation therapy for allogenic haematopoietic stem cell transplantation in patients affected by Thalassemia Major. Sponsor: IRSS San Raffaele, Milano.

2007              Protocol Allotreo Emato-oncologia. Clinical multicentric phase II study to evaluate the security and effectiveness of the Treosulfan drug in the preparation therapy for allogenic haematopoietic stem cell transplantation in patients affected by haematological malignancies. Sponsor: IRSS San Raffaele, Milano.

2006              Protocol GIMEMA AML19. Gentuzumab Ozogamicin monotherapy vs. supportive care in elderly non-treated patients affected by Acute Myeloid Leukaemia untreatable with intensive chemotherapy: a randomized phase II trial. Sponsor: Gruppo Italiano Malattie Ematologiche dell’Adulto.

2006              Protocol GIMEMA AML17. Gentuzumab Ozogamicin combined with induction-consolidation standard chemotherapy in 61-75 year old patients affected by Acute Myeloid Leukaemia: a randomized phase II trial. Sponsor: Gruppo Italiano Malattie Ematologiche dell’Adulto.

Clinical activity

2011-         Researcher in hematology cooperating with the Bone Marrow Transplantation Centre of the Hospital “Binaghi”, ASL 8 (Cagliari)

2000-10     Attending Haematology physician in the Bone Marrow Transplantation Centre of the Hospital “Binaghi”, ASL 8 (Cagliari)

2000-10    Clinical care on patients affected by all the kinds of onco-haematological diseases, congenital and acquired anaemias in the Bone Marrow Transplantation Centre of the Hospital “Binaghi”, ASL 8 (Cagliari)

2000-10      Carrying out of over 3500 internist-haematological ultrasounds in the Bone Marrow Transplantation Centre of the Hospital “Binaghi”, ASL 8 (Cagliari)

1998-00     Physician assistant in the Medicine Ward of the General Hospital S. Elena (Cagliari). Cooperation in the computerization of patients’ medical reports and organization of a newly created ward.

1998-00     Carrying out of over 2000 internist ultrasounds in the Medicine Ward of the General Hospital S. Elena (Cagliari).

1998           National Diploma of Clinical Ultrasound. Società italiana di Ultrasonologia (SIUMB).

1994-97      Internal Physician in the wards of the Medical Clinic of the University of Cagliari. Care of patients affected by internal diseases, especially haematological and hereditary congenital hepatological ones.

1993-94      Medical Lieutenant and medical direction of the local infirmary during military service.

1988-92      Internal student in the II Medical Clinic of the University of Cagliari, Gastroenterology Department

 

Organization, direction and coordination of national and international research groups:

Prof. Caocci has been the Co-Chairman of the Working Group on Quality of Life (QoL-WG) and of the Italian Group of Haematological Diseases (GIMEMA), directed by Prof. Mandelli – Rome – (coordinator of over 120 Italian haematological centres carrying out research experimental protocols relating the issue of quality of life in haematological patients) since 2010. The QoL-WG also cooperates with European Cancer Research Centres, such as EORTC, and has presented several scientific communications in international congresses on onco-haematology (ASH, EHA, ASCO) so far. 

2010 –  today          Co-Chairman of the Working Group on Quality of Life (QoL-WG) and of the the Italian Group of Haematological Diseases (GIMEMA).

Attendance as Speaker in national and international congresses

Prof. Caocci has presented several reports in English in international and national congresses of Haematology. 

 

Reports in international congresses:

 “Critical points in diagnosis and prognostic evaluation of MDS” and “QoL: the value of Promys registry” in: Bridge Educational Meeting on HR-MDS and AML 20-30% blasts. 12 Ottobre 2016, Cagliari, Italy

“Stem cell in thalassemia”. In: 11th International workshop on Neonatology, Cagliari, 7 ottobre 2015

“Patient and physician concordance in treatment decision and health status evaluation in patients with higher-risk myelodysplasic syndromes” in: European Association of Centres of Medical Ethics (EACME) annual congress, Cagliari, 19 Sep 2015

“Accuracy of physician assessment of treatment preferences and health status in patients with higher-risk MDS syndromes” in: 20th Annual congress of the European Hematology Association (EHA), Vienna, 12 June 2015

“Homozygosity for Killer Immunoglobin-like Receptor (KIR) Haplotype a Is Associated to Negative Interim Positron Emission Tomography (PET) and a Favourable Outcome in Hodgkin Lymphoma” in: 56th Annual Meeting of the American Society of Hematology (ASH), San Francisco,(CA), USA. 7 Dec 2014.

“Long term quality of life after more than 20 years after HSCT in thalassemia” in: European Bone Marrow Transplantation (EBMT) 40° meeting 2014. Milano (IT), 1 Apr 2014

“Transplant issues in thalassemia” in: 8th Patient, Family & Donor Day. Milano (IT), 29 Mar 2014

“Quality of life in thalassemia patients twenty years after transplantation: long term outcome and return to normal lifestyle” in: European Bone Marrow Transplantation (EBMT) 39° meeting 2013. London (GB), 10 Apr 2013

“Tools predicting HSCT Outcome” Teaching Session in: 25th European Immunogenetics and Histocompatibility Conference. Prague, 6 may 2011

“Longitudinal assessment of health-related quality of life and healthcare satisfaction after haematopoietic stem cell transplantation in children with thalassaemia” in: European Bone Marrow Transplantation (EBMT) 37 meeting 2010. Vienna (Austria), 24 March 2010

“Unrelated bone marrow transplantation in talassemia”. An international course given by: Karolinska Institutet, Stockholm. Uniwersitytet Jagiellonska, Krakow and Universitá degli Studi di Cagliari, Cagliari. Medical Development in Europe: winter module, Cagliari, 11 January 2009.

“Bias in physician-patient communication during informed consent for unrelated HSCT in adult thalassaemia patients” in: European Bone Marrow Transplantation EBMT meeting 2008. Florence (Italy), 31 March 2008.

Prof Caocci has given more than 100 Reports in national congresses

Membership in Scientific Societies

2020-           Member of the American Society of Hematology

2008-10        Member of the Italian Bone Marrow Transplant Group (GITMO).

Pubblications:

Dr Caocci is author or co-author of 130 international publications listed in Pubmed 

1: Breccia M, Pregno P, Castagnetti F, Bonifacio M, Tiribelli M, Gozzini A,

Scortechini AR, Luciano L, Martino B, Stagno F, Caocci G, La Barba G, Pizzuti M,

Ciccone G, Saglio G, Specchia G. Eutos long-term survival score discriminates

different Sokal score categories in chronic myeloid leukemia patients, showing

better survival prediction. Analysis of the GIMEMA CML observational study.

Leukemia. 2021 May 17. doi: 10.1038/s41375-021-01292-4. Epub ahead of print.

PMID: 34002030.

2: Sancassiani F, Massa E, Pibia C, Perda G, Boe L, Fantozzi E, Cossu G, Caocci

G, Mulas O, Morelli E, Lindert J, Lai E, Nardi AE, Scartozzi M, La Nasa G, Carta

MG. The association between Major Depressive Disorder and premature death risk

in hematologic and solid cancer: a longitudinal cohort study. J Public Health

Res. 2021 May 5. doi: 10.4081/jphr.2021.2247. Epub ahead of print. PMID:

33960184.

3: Palandri F, Rossi E, Bartoletti D, Ferretti A, Ruggeri M, Lucchini E, Carrai

V, Barcellini W, Patriarca A, Rivolti E, Consoli U, Cantoni S, Oliva EN,

Chiurazzi F, Caocci G, Giuffrida G, Borchiellini A, Auteri G, Baldacci E, Carli

G, Nicolosi D, Sutto E, Carpenedo M, Cavo M, Mazzucconi MG, Zaja F, De Stefano

V, Rodeghiero F, Vianelli N. Real-world use of thrombopoietin receptor agonists

in elderly patients with primary immune thrombocytopenia. Blood. 2021 Apr

22:blood.2021010735. doi: 10.1182/blood.2021010735. Epub ahead of print. PMID:

33889952.

4: Palandri F, Tiribelli M, Breccia M, Bartoletti D, Elli EM, Benevolo G,

Martino B, Cavazzini F, Tieghi A, Iurlo A, Abruzzese E, Pugliese N, Binotto G,

Caocci G, Auteri G, Cattaneo D, Trawinska MM, Stella R, Scaffidi L, Polverelli

N, Micucci G, Masselli E, Crugnola M, Bosi C, Heidel FH, Latagliata R, Pane F,

Cuneo A, Krampera M, Semenzato G, Lemoli RM, Cavo M, Vianelli N, Bonifacio M,

Palumbo GA. Ruxolitinib rechallenge in resistant or intolerant patients with

myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer.

2021 Apr 1. doi: 10.1002/cncr.33541. Epub ahead of print. PMID: 33794557.

5: Gamper EM, Cottone F, Sommer K, Norman R, King M, Breccia M, Caocci G,

Patriarca A, Palumbo GA, Stauder R, Niscola P, Platzbecker U, Caers J, Vignetti

M, Efficace F. The EORTC QLU-C10D was more efficient in detecting clinical known

group differences in myelodysplastic syndromes than the EQ-5D-3L. J Clin

Epidemiol. 2021 Mar 20;137:31-44. doi: 10.1016/j.jclinepi.2021.03.015. Epub

ahead of print. PMID: 33753228.

6: Scalzulli E, Caocci G, Efficace F, Rizzo L, Colafigli G, Di Prima A, Pepe S,

Fegatelli DA, Carmosino I, Diverio D, Latagliata R, La Nasa G, Martelli M, Foà

R, Breccia M. Real-life comparison of nilotinib versus dasatinib as second-line

therapy in chronic phase chronic myeloid leukemia patients. Ann Hematol. 2021

May;100(5):1213-1219. doi: 10.1007/s00277-021-04477-0. Epub 2021 Mar 7. PMID:

33677654.

7: Latagliata R, Attolico I, Trawinska MM, Capodanno I, Annunziata M, Elena C,

Luciano L, Crugnola M, Bergamaschi M, Bonifacio M, Baratè C, Mauro E, Binotto G,

Sgherza N, Aguzzi C, Monteleone B, Sorà F, Caocci G, Luzi D, Mariggiò E,

Scaffidi L, Cattaneo D, Gozzini A, Di Veroli A, Abruzzese E, Galimberti S, Iurlo

A, Specchia G, Breccia M. Bosutinib in the real-life treatment of chronic

myeloid leukemia patients aged >65 years resistant/intolerant to previous

tyrosine-kinase inhibitors. Hematol Oncol. 2021 Feb 22. doi: 10.1002/hon.2851.

Epub ahead of print. PMID: 33617659.

8: Benevolo G, Elli EM, Bartoletti D, Latagliata R, Tiribelli M, Heidel FH,

Cavazzini F, Bonifacio M, Crugnola M, Binotto G, D'Addio A, Tieghi A,

Bergamaschi M, Caocci G, Polverelli N, Bossi E, Auteri G, Carmosino I, Catani L,

Cuneo A, Krampera M, Lanza F, Lemoli RM, Vianelli N, Breccia M, Palumbo GA, Cavo

M, Palandri F. Impact of comorbidities and body mass index on the outcome of

polycythemia vera patients. Hematol Oncol. 2021 Feb 15. doi: 10.1002/hon.2843.

Epub ahead of print. PMID: 33590502.

9: Acquaviva G, Nonne G, Murtas A, Longu F, Caocci G, La Nasa G, Fozza C.

Cytomegalovirus reactivation in patients under immunosuppressive treatment for

autoimmune haemolytic anaemia. Ann Hematol. 2021 Jan 19. doi:

10.1007/s00277-021-04416-z. Epub ahead of print. PMID: 33469687.

10: Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B,

Abruzzese E, Tiribelli M, Tieghi A, Latagliata R, Cavazzini F, Bergamaschi M,

Binotto G, Crugnola M, Isidori A, Caocci G, Heidel F, Pugliese N, Bosi C,

Bartoletti D, Auteri G, Cattaneo D, Scaffidi L, Trawinska MM, Stella R, Ciantia

F, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Iurlo A, Vianelli N,

Cavo M, Breccia M, Bonifacio M. Ruxolitinib discontinuation syndrome: incidence,

risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J.

2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1. PMID: 33414394; PMCID:

PMC7791065.

11: Caocci G, Mulas O, Capodanno I, Bonifacio M, Annunziata M, Galimberti S,

Luciano L, Tiribelli M, Martino B, Castagnetti F, Binotto G, Pregno P, Stagno F,

Abruzzese E, Bocchia M, Gozzini A, Albano F, Fozza C, Luzi D, Efficace F, Simula

MP, Scaffidi L, Baratè C, De Gregorio F, Stella R, Gugliotta G, Pirillo F,

Trawinska MM, Sicuranza A, Cattaneo D, Attolico I, Scalzulli E, Iurlo A, Foà R,

Breccia M, La Nasa G. Low-density lipoprotein (LDL) levels and risk of arterial

occlusive events in chronic myeloid leukemia patients treated with nilotinib.

Ann Hematol. 2021 Jan 3. doi: 10.1007/s00277-020-04392-w. Epub ahead of print.

PMID: 33388860.

12: Saba L, Gerosa C, Fanni D, Marongiu F, La Nasa G, Caocci G, Barcellona D,

Balestrieri A, Coghe F, Orru G, Coni P, Piras M, Ledda F, Suri JS, Ronchi A,

D'Andrea F, Cau R, Castagnola M, Faa G. Molecular pathways triggered by COVID-19

in different organs: ACE2 receptor-expressing cells under attack? A review. Eur

Rev Med Pharmacol Sci. 2020 Dec;24(23):12609-12622. doi:

10.26355/eurrev_202012_24058. PMID: 33336781.

13: Carruale A, Longu F, Mura F, Caocci G, La Nasa G, Fozza C. Occurrence of

immune thrombocytopenic purpura in a patient with essential thrombocythemia: How

the immune system can overcome a neoplastic clone. Clin Case Rep. 2020 Jul

17;8(11):2132-2134. doi: 10.1002/ccr3.3121. PMID: 33235743; PMCID: PMC7669383.

14: Polverelli N, Elli EM, Abruzzese E, Palumbo GA, Benevolo G, Tiribelli M,

Bonifacio M, Tieghi A, Caocci G, D'Adda M, Bergamaschi M, Binotto G, Heidel FH,

Cavazzini F, Crugnola M, Pugliese N, Bosi C, Isidori A, Bartoletti D, Auteri G,

Latagliata R, Gandolfi L, Martino B, Scaffidi L, Cattaneo D, D'Amore F,

Trawinska MM, Stella R, Markovic U, Catani L, Pane F, Cuneo A, Krampera M,

Semenzato G, Lemoli RM, Vianelli N, Breccia M, Russo D, Cavo M, Iurlo A,

Palandri F. Second primary malignancy in myelofibrosis patients treated with

ruxolitinib. Br J Haematol. 2021 Apr;193(2):356-368. doi: 10.1111/bjh.17192.

Epub 2020 Nov 21. PMID: 33222197.

15: Dragani M, Rege Cambrin G, Berchialla P, Dogliotti I, Rosti G, Castagnetti

F, Capodanno I, Martino B, Cerrano M, Ferrero D, Gambacorti-Passerini C,

Crugnola M, Elena C, Breccia M, Iurlo A, Cattaneo D, Galimberti S, Gozzini A,

Bocchia M, Lunghi F, Cedrone M, Sgherza N, Luciano L, Russo S, Santoro M, Giai

V, Caocci G, Levato L, Abruzzese E, Sora F, Saglio G, Fava C. A Retrospective

Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia

Patients after Discontinuation. J Clin Med. 2020 Nov 17;9(11):3692. doi:

10.3390/jcm9113692. PMID: 33213044; PMCID: PMC7698481.

16: Fontana D, Ramazzotti D, Aroldi A, Redaelli S, Magistroni V, Pirola A, Niro

A, Massimino L, Mastini C, Brambilla V, Bombelli S, Bungaro S, Morotti A, Rea D,

Stagno F, Martino B, Campiotti L, Caocci G, Usala E, Merli M, Onida F, Bregni M,

Elli EM, Fumagalli M, Ciceri F, Perego RA, Pagni F, Mologni L, Piazza R,

Gambacorti-Passerini C. Integrated Genomic, Functional, and Prognostic

Characterization of Atypical Chronic Myeloid Leukemia. Hemasphere. 2020 Nov

6;4(6):e497. doi: 10.1097/HS9.0000000000000497. PMID: 33196013; PMCID:

PMC7655091.

17: Efficace F, Iurlo A, Patriarca A, Stagno F, Bee PC, Ector G, Capodanno I,

Elena C, Bonifacio M, Blijlevens NMA, Caocci G, Wan C, Abruzzese E, Breccia M,

Cottone F, Okumura I, Oerlemans S, Cascavilla N, Albano F, Kota V, Sztankay M,

Miggiano MC, Saussele S, Di Renzo N, Sorà F, Castagnetti F, Baccarani M,

Vignetti M, Rosti G. Validation and reference values of the EORTC QLQ-CML24

questionnaire to assess health-related quality of life in patients with chronic

myeloid leukemia. Leuk Lymphoma. 2021 Mar;62(3):669-678. doi:

10.1080/10428194.2020.1838509. Epub 2020 Nov 6. PMID: 33153355.

18: Pilo F, Caocci G, Mele G, La Nasa G. Perls Stain Grade in Bone Marrow

Aspirate Correlates with Overall Survival in Low-Risk Myelodysplastic Patients.

Acta Haematol. 2021;144(3):332-336. doi: 10.1159/000510111. Epub 2020 Oct 2.

PMID: 33011720.

19: Dragani M, Petiti J, Rege-Cambrin G, Gottardi E, Daraio F, Caocci G, Aguzzi

C, Crisà E, Andreani G, Caciolli F, Fava C. Treatment-Free Remission in Chronic

Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts. Mediterr J Hematol

Infect Dis. 2020 Sep 1;12(1):e2020066. doi: 10.4084/MJHID.2020.066. PMID:

32952977; PMCID: PMC7485467.

20: Marras T, Dettori M, Caocci G, La Nasa G, Sotgiu G, Saderi L, Fozza C. White

Blood Cell Count Nadir and Duration of Aplasia Do Not Associate with Treatment

Outcome in Adult Patients with Acute Myeloid Leukemia Undergoing Intensive

Chemotherapy. Chemotherapy. 2020;65(3-4):110-114. doi: 10.1159/000509816. Epub

2020 Sep 18. PMID: 32950983.

21: Macciò A, Madeddu C, Caocci G, Oppi S, La Nasa G. Defibrotide in the

COVID-19 coagulopathy: What is the timing? J Thromb Haemost. 2020

Nov;18(11):3113-3115. doi: 10.1111/jth.15100. PMID: 32945111; PMCID: PMC7537223.

22: Mulas O, Caocci G, Dessì D, Mantovani D, Moi G, Cabras MG, La Nasa G.

Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to

Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone

Lymphoma in the Real Life. Acta Haematol. 2021;144(3):322-326. doi:

10.1159/000509596. Epub 2020 Sep 4. PMID: 32892194.

23: La Nasa G, Caocci G, Morelli E, Massa E, Farci A, Deiana L, Pintus E,

Scartozzi M, Sancassiani F. Health Related Quality of Life in Patients with

Onco-hematological Diseases. Clin Pract Epidemiol Ment Health. 2020 Jul

30;16:174-179. doi: 10.2174/1745017902016010174. PMID: 32874192; PMCID:

PMC7431682.

24: Sica M, Pellecchia A, De Angioletti M, Caocci G, Nannelli C, La Nasa G,

Luzzatto L, Notaro R. Complement-mediated oxidative damage of red cells impairs

response to eculizumab in a G6PD-deficient patient with PNH. Blood. 2020 Dec

24;136(26):3082-3085. doi: 10.1182/blood.2020007780. PMID: 32845970.

25: Pilz MJ, Aaronson NK, Arraras JI, Caocci G, Efficace F, Groenvold M, Holzner

B, van Leeuwen M, Loth FLC, Petersen MA, Ramage J, Tomaszewski KA, Young T,

Giesinger JM. Evaluating the Thresholds for Clinical Importance of the EORTC

QLQ-C15-PAL in Patients Receiving Palliative Treatment. J Palliat Med. 2021

Mar;24(3):397-404. doi: 10.1089/jpm.2020.0159. Epub 2020 Aug 24. PMID: 32835601.

26: Macciò A, Madeddu C, Caocci G, La Nasa G. Multifactorial pathogenesis of

COVID-19-related coagulopathy: Can defibrotide have a role in the early phases

of coagulation disorders? J Thromb Haemost. 2020 Nov;18(11):3106-3108. doi:

10.1111/jth.15021. PMID: 32692894; PMCID: PMC7405280.

27: Mulas O, Caocci G, Annunziata M, Martino B, Luciano L, Castagnetti F, Pregno

P, Galimberti S, Albano F, Orlandi EM, Sgherza N, Iurlo A, Bonifacio M, Binotto

G, Gozzini A, Bocchia M, Abruzzese E, Fozza C, Simula MP, De Gregorio F,

Gugliotta G, Pirillo F, Baratè C, Attolico I, Elena C, Cattaneo D, Scaffidi L,

Sicuranza A, Trawinska MM, Scalzulli E, Foà R, Breccia M, La Nasa G. Favorable

outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts,

treated with nilotinib. Hematol Oncol. 2020 Oct;38(4):607-610. doi:

10.1002/hon.2765. Epub 2020 Jul 23. PMID: 32602167.

28: Caocci G, Vignetti M, Patriarca A, Breccia M, Platzbecker U, Palumbo GA,

Stauder R, Cottone F, Petranovic D, Voso MT, Tafuri A, Invernizzi R, Caers J,

Luppi M, La Nasa G, Niscola P, Efficace F. High serum ferritin levels in newly

diagnosed patients with myelodysplastic syndromes are associated with greater

symptom severity. Int J Hematol. 2020 Aug;112(2):141-146. doi:

10.1007/s12185-020-02920-y. Epub 2020 Jun 25. PMID: 32588394.

29: Iurlo A, Cattaneo D, Malato A, Accurso V, Annunziata M, Gozzini A,

Scortechini AR, Bucelli C, Scalzulli E, Attolico I, Maggi A, Martino B, Caocci

G, Abruzzese E, Pregno P, Luciano L, Breccia M. Low-dose ponatinib is a good

option in chronic myeloid leukemia patients intolerant to previous TKIs. Am J

Hematol. 2020 Oct;95(10):E260-E263. doi: 10.1002/ajh.25908. Epub 2020 Jul 7.

PMID: 32557788.

30: Caocci G, Mulas O, Capodanno I, Abruzzese E, Iurlo A, Luciano L, Albano F,

Annunziata M, Tiribelli M, Bonifacio M, Galimberti S, Castagnetti F, Sgherza N,

Stagno F, Gozzini A, Orlandi EM, Luzi D, Binotto G, Pregno P, Fozza C, Efficace

F, Simula MP, Trawinska MM, Cattaneo D, De Gregorio F, Attolico I, Stella R,

Scaffidi L, Baratè C, Gugliotta G, Scalzulli E, Elena C, Pirillo F, Foà R,

Breccia M, Nasa G. Low low-density lipoprotein (LDL), cholesterol and

triglycerides plasma levels are associated with reduced risk of arterial

occlusive events in chronic myeloid leukemia patients treated with ponatinib in

the real-life. A Campus CML study. Blood Cancer J. 2020 Jun 8;10(6):66. doi:

10.1038/s41408-020-0333-2. PMID: 32514110; PMCID: PMC7280258.

31: Mulas O, Caocci G, Stagno F, Bonifacio M, Annunziata M, Luciano L, Orlandi

EM, Abruzzese E, Sgherza N, Martino B, Albano F, Galimberti S, Pregno P, Bocchia

M, Castagnetti F, Tiribelli M, Binotto G, Gozzini A, Capodanno I, Fozza C, Luzi

D, Efficace F, Simula MP, Scaffidi L, De Gregorio F, Elena C, Trawinska MM,

Cattaneo D, Attolico I, Baratè C, Pirillo F, Sicuranza A, Gugliotta G, Stella R,

Scalzulli E, Iurlo A, Foà R, Breccia M, La Nasa G. Renin angiotensin system

inhibitors reduce the incidence of arterial thrombotic events in patients with

hypertension and chronic myeloid leukemia treated with second- or third-

generation tyrosine kinase inhibitors. Ann Hematol. 2020 Jul;99(7):1525-1530.

doi: 10.1007/s00277-020-04102-6. Epub 2020 May 30. PMID: 32474619.

32: Greco M, Caocci G, Mascia R, Nemolato S, Deidda M, Simula MP, Barca MP, Orrù

S, La Nasa G. Systemic Mastocytosis with Associated Primary Myelofibrosis.

Indian J Hematol Blood Transfus. 2020 Apr;36(2):442-443. doi:

10.1007/s12288-019-01225-3. Epub 2019 Oct 28. PMID: 32425413; PMCID: PMC7229127.

33: Caocci G, La Nasa G. Could ruxolitinib be effective in patients with

COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? Ann

Hematol. 2020 Jul;99(7):1675-1676. doi: 10.1007/s00277-020-04067-6. Epub 2020

May 14. PMID: 32405693; PMCID: PMC7220809.

34: Caocci G, Deidda M, Noto A, Greco M, Simula MP, Mulas O, Cocco D, Fattuoni

C, Mercuro G, La Nasa G, Cadeddu Dessalvi C. Metabolomic Analysis of Patients

with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment

with Tyrosine Kinase Inhibitors. J Clin Med. 2020 Apr 20;9(4):1180. doi:

10.3390/jcm9041180. PMID: 32326001; PMCID: PMC7231160.

35: Caocci G, Simula MP, Ghiani S, Mulas O, Mainas G, Atzeni S, Pettinau M,

Usala E, La Nasa G. Increased incidence of infection in patients with

myelofibrosis and transfusion-associated iron overload in the clinical setting.

Int J Hematol. 2020 May;111(5):614-618. doi: 10.1007/s12185-020-02861-6. Epub

2020 Mar 23. PMID: 32207052.

36: Massaiu R, Longu F, Podda L, Mura F, Caocci G, La Nasa G, Fara AM, Deiana A,

Cossu AGM, Crivelli P, Conti M, Pala C, Carboni L, Scognamillo F, Fozza C.

Rectal involvement in pre-early T acute lymphoblastic leukemia. Ann Hematol.

2020 May;99(5):1151-1152. doi: 10.1007/s00277-020-03998-4. Epub 2020 Mar 16.

PMID: 32179989.

37: Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, Breccia

M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers

J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P,

Vignetti M. The IPSS-R more accurately captures fatigue severity of newly

diagnosed patients with myelodysplastic syndromes compared with the IPSS index.

Leukemia. 2020 Sep;34(9):2451-2459. doi: 10.1038/s41375-020-0746-8. Epub 2020

Feb 21. PMID: 32086447; PMCID: PMC7509847.

38: Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S,

Beltrami G, Bergamaschi M, Binotto G, Bocchia M, Caocci G, Capodanno I,

Cavazzini F, Cedrone M, Cerrano M, Crugnola M, D'Adda M, Elena C, Fava C, Fazi

P, Fozza C, Galimberti S, Giai V, Gozzini A, Gugliotta G, Iurlo A, La Barba G,

Levato L, Lucchesi A, Luciano L, Lunghi F, Lunghi M, Malagola M, Marasca R,

Martino B, Melpignano A, Miggiano MC, Montefusco E, Musolino C, Palmieri F,

Pregno P, Rapezzi D, Rege-Cambrin G, Rupoli S, Salvucci M, Sancetta R, Sica S,

Spadano R, Stagno F, Tiribelli M, Tomassetti S, Trabacchi E, Bonifacio M,

Breccia M, Castagnetti F, Pane F, Russo D, Saglio G, Soverini S, Vigneri P,

Rosti G. Managing chronic myeloid leukemia for treatment-free remission: a

proposal from the GIMEMA CML WP. Blood Adv. 2019 Dec 23;3(24):4280-4290. doi:

10.1182/bloodadvances.2019000865. PMID: 31869412; PMCID: PMC6929396.

39: Caocci G, Greco M, Frau V, Asproni R, Piras G, Palmas A, Casula P, La Nasa

G. Systemic mastocytosis with associated BCRABL1-negative atypical chronic

myeloid leukemia. Ann Hematol. 2020 Feb;99(2):363-365. doi:

10.1007/s00277-019-03875-9. Epub 2019 Dec 6. PMID: 31807857.

40: Caocci G, Mulas O, Annunziata M, Luciano L, Abruzzese E, Bonifacio M,

Orlandi EM, Albano F, Galimberti S, Iurlo A, Pregno P, Sgherza N, Martino B,

Binotto G, Castagnetti F, Gozzini A, Bocchia M, Fozza C, Stagno F, Simula MP, De

Gregorio F, Trawinska MM, Scaffidi L, Elena C, Attolico I, Baratè C, Cattaneo D,

Pirillo F, Gugliotta G, Sicuranza A, Molica M, La Nasa G, Foà R, Breccia M.

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid

leukaemia patients treated with second- and third-generation tyrosine kinase

inhibitors. Int J Cardiol. 2020 Feb 15;301:163-166. doi:

10.1016/j.ijcard.2019.10.036. Epub 2019 Oct 24. PMID: 31711851.

41: Efficace F, Cottone F, Sommer K, Kieffer J, Aaronson N, Fayers P, Groenvold

M, Caocci G, Lo Coco F, Gaidano G, Niscola P, Baccarani M, Rosti G, Venditti A,

Angelucci E, Fazi P, Vignetti M, Giesinger J. Validation of the European

Organisation for Research and Treatment of Cancer Quality of Life Questionnaire

Core 30 Summary Score in Patients With Hematologic Malignancies. Value Health.

2019 Nov;22(11):1303-1310. doi: 10.1016/j.jval.2019.06.004. Epub 2019 Aug 7.

PMID: 31708068.

42: Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F,

Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T,

Holzner B; EORTC Quality of Life Group. Thresholds for clinical importance were

established to improve interpretation of the EORTC QLQ-C30 in clinical practice

and research. J Clin Epidemiol. 2020 Feb;118:1-8. doi:

10.1016/j.jclinepi.2019.10.003. Epub 2019 Oct 19. PMID: 31639445.

43: Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F,

Groenvold M, van Leeuwen M, Petersen MA, Ramage J, Tomaszewski KA, Young T,

Holzner B; EORTC Quality of Life Group. Thresholds for clinical importance were

defined for the European Organisation for Research and Treatment of Cancer

Computer Adaptive Testing Core-an adaptive measure of core quality of life

domains in oncology clinical practice and research. J Clin Epidemiol. 2020

Jan;117:117-125. doi: 10.1016/j.jclinepi.2019.09.028. Epub 2019 Oct 5. PMID:

31593797.

44: Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese

E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M,

Patriarca A, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi

M, Binotto G, Vignetti M, Rosti G. Health-related quality of life of newly

diagnosed chronic myeloid leukemia patients treated with first-line dasatinib

versus imatinib therapy. Leukemia. 2020 Feb;34(2):488-498. doi:

10.1038/s41375-019-0563-0. Epub 2019 Sep 2. PMID: 31477798.

45: Fozza C, La Nasa G, Caocci G. The Yin and Yang of myelodysplastic syndromes

and autoimmunity: The paradox of autoimmune disorders responding to therapies

specific for MDS. Crit Rev Oncol Hematol. 2019 Oct;142:51-57. doi:

10.1016/j.critrevonc.2019.07.018. Epub 2019 Jul 26. PMID: 31376677.

46: Crobu V, Caocci G, La Nasa G, Saderi L, Sotgiu G, Fozza C. A Real-World

Study on Clofarabine and Cytarabine Combination in Patients with

Relapsed/Refractory Acute Myeloid Leukemia. Mediterr J Hematol Infect Dis. 2019

May 1;11(1):e2019032. doi: 10.4084/MJHID.2019.032. PMID: 31205636; PMCID:

PMC6548210.

47: Breccia M, Luciano L, Pugliese N, Rossi E, Tiribelli M, Scalzulli E,

Bonifacio M, Martino B, Latagliata R, Benevolo G, Caocci G, Binotto G,

Martinelli V, Cavo M, Pane F, De Stefano V, Foà R, Palandri F. Efficacy and

safety of ruxolitinib and hydroxyurea combination in patients with

hyperproliferative myelofibrosis. Ann Hematol. 2019 Aug;98(8):1933-1936. doi:

10.1007/s00277-019-03727-6. Epub 2019 Jun 14. PMID: 31201513.

48: Caocci G, Mulas O, Abruzzese E, Iurlo A, Annunziata M, Orlandi EM,

Galimberti S, Binotto G, Sgherza N, Luciano L, Martino B, Russo Rossi A,

Bonifacio M, Fozza C, Trawinska MM, Cattaneo D, Elena C, Baratè C, De Gregorio

F, Molica M, La Nasa G, Foà R, Breccia M. Incidence and evaluation of

predisposition to cardiovascular toxicity in chronic myeloid leukemia patients

treated with bosutinib in the real-life practice. Ann Hematol. 2019

Aug;98(8):1885-1890. doi: 10.1007/s00277-019-03705-y. Epub 2019 May 1. PMID:

31044260.

49: Caocci G, Mulas O, Bonifacio M, Abruzzese E, Galimberti S, Orlandi EM, Iurlo

A, Annunziata M, Luciano L, Castagnetti F, Gozzini A, Stagno F, Binotto G,

Pregno P, Albano F, Martino B, Fozza C, Scaffidi L, Trawinska MM, Baratè C,

Elena C, Cattaneo D, Scalzulli E, La Nasa G, Foà R, Breccia M. Recurrent

arterial occlusive events in patients with chronic myeloid leukemia treated with

second- and third-generation tyrosine kinase inhibitors and role of secondary

prevention. Int J Cardiol. 2019 Aug 1;288:124-127. doi:

10.1016/j.ijcard.2019.04.051. Epub 2019 Apr 17. PMID: 31029498.

50: Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti

F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM,

Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D,

Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La

Nasa G, Foà R, Breccia M. Arterial occlusive events in chronic myeloid leukemia

patients treated with ponatinib in the real-life practice are predicted by the

Systematic Coronary Risk Evaluation (SCORE) chart. Hematol Oncol. 2019

Aug;37(3):296-302. doi: 10.1002/hon.2606. Epub 2019 Apr 17. PMID: 30892724;

PMCID: PMC6766852.

51: Carruale A, Muntone G, Rojas R, Bonfigli S, Virdis P, Longu F, Valdes G,

Piras G, Uras A, Palmas A, Caocci G, La Nasa G, Fozza C. Acute basophilic

leukemia with U2AF1 mutation. Blood Cells Mol Dis. 2019 May;76:63-65. doi:

10.1016/j.bcmd.2019.02.002. Epub 2019 Feb 22. PMID: 30827760.

52: Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M,

Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C,

Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola

M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R,

Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F,

Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F,

Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G. Observational

study of chronic myeloid leukemia Italian patients who discontinued tyrosine

kinase inhibitors in clinical practice. Haematologica. 2019

Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28. PMID:

30819917; PMCID: PMC6669161.

53: Raspadori D, Pacelli P, Sicuranza A, Abruzzese E, Iurlo A, Cattaneo D,

Gozzini A, Galimberti S, Baratè C, Pregno P, Nicolosi M, Sorà F, Annunziata M,

Luciano L, Caocci G, Moretti S, Sgherza N, Fozza C, Russo S, Usala E, Liberati

MA, Ciofini S, Trawinska MM, Gozzetti A, Bocchia M. Flow Cytometry Assessment of

CD26<sup>+</sup> Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New

Diagnostic Tool for Chronic Myeloid Leukemia. Cytometry B Clin Cytom. 2019

Jul;96(4):294-299. doi: 10.1002/cyto.b.21764. Epub 2019 Feb 3. PMID: 30714299;

PMCID: PMC6767040.

54: Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A,

Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C,

Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C,

Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M,

Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D.

Residual Peripheral Blood CD26<sup>+</sup> Leukemic Stem Cells in Chronic

Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free

Remission. Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. PMID:

29900128; PMCID: PMC5988870.

55: Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno

P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N,

Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F,

Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C,

Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa

G, Foà R, Breccia M. Cardiovascular toxicity in patients with chronic myeloid

leukemia treated with second-generation tyrosine kinase inhibitors in the real-

life practice: Identification of risk factors and the role of prophylaxis. Am J

Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28.

PMID: 29633312.

56: Caocci G, Ghiani S, Mocci C, La Nasa G. Combination Therapy with Ruxolitinib

and Hydroxyurea for the Treatment of Myeloid-Predominant Leukocytosis in a

Patient with Myelofibrosis. Acta Haematol. 2018;139(3):164-165. doi:

10.1159/000487582. Epub 2018 Mar 29. PMID: 29597187.

57: Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S,

Mecucci C; MORE Study Centres. Lenalidomide treatment of myelodysplastic

syndromes with chromosome 5q deletion: Results from the National Registry of the

Italian Drug Agency. Eur J Haematol. 2018 Jul;101(1):78-85. doi:

10.1111/ejh.13067. Epub 2018 May 22. PMID: 29569278.

58: Breccia M, Palandri F, Luciano L, Benevolo G, Bonifacio M, Caocci G,

Castagnetti F, Palumbo GA, Iurlo A, Landi F. Identification and assessment of

frailty in older patients with chronic myeloid leukemia and myelofibrosis, and

indications for tyrosine kinase inhibitor treatment. Ann Hematol. 2018

May;97(5):745-754. doi: 10.1007/s00277-018-3258-0. Epub 2018 Feb 22. PMID:

29468276.

59: Caocci G, Atzeni S, Usai M, La Nasa G. Essential thrombocytemia following

immune thrombocytopenia with JAK2V617F mutation. Leuk Res Rep. 2017 Dec

27;9:14-15. doi: 10.1016/j.lrr.2017.12.002. PMID: 29326868; PMCID: PMC5758937.

60: Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, Anota A,

Caocci G, Cronin A, Fianchi L, Breccia M, Stauder R, Platzbecker U, Palumbo GA,

Luppi M, Invernizzi R, Bergamaschi M, Borin L, Di Tucci AA, Zhang H, Sprangers

M, Vignetti M, Mandelli F. Patient-reported outcomes enhance the survival

prediction of traditional disease risk classifications: An international study

in patients with myelodysplastic syndromes. Cancer. 2018 Mar

15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12. PMID: 29231969.

61: Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini

F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco

F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D,

Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G,

Cortelezzi A, Petrini M, Iurlo A, Di Paolo A. The <i>hOCT1</i> and <i>ABCB1</i>

polymorphisms do not influence the pharmacodynamics of nilotinib in chronic

myeloid leukemia. Oncotarget. 2017 Sep 30;8(50):88021-88033. doi:

10.18632/oncotarget.21406. PMID: 29152138; PMCID: PMC5675690.

62: van de Poll-Franse L, Oerlemans S, Bredart A, Kyriakou C, Sztankay M, Pallua

S, Daniëls L, Creutzberg CL, Cocks K, Malak S, Caocci G, Molica S, Chie W,

Efficace F; EORTC Quality of Life Group. International development of four EORTC

disease-specific quality of life questionnaires for patients with Hodgkin

lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic

leukaemia. Qual Life Res. 2018 Feb;27(2):333-345. doi:

10.1007/s11136-017-1718-y. Epub 2017 Nov 10. PMID: 29127596; PMCID: PMC5846994.

63: Sanna M, Caocci G, La Nasa G. How We Manage Invasive Fungal Disease in Acute

Myeloid Leukemia Patients with Glucose 6 Dehydrogenase Deficiency. Mediterr J

Hematol Infect Dis. 2017 Aug 14;9(1):e2017047. doi: 10.4084/MJHID.2017.047.

PMID: 28894556; PMCID: PMC5584773.

64: Caocci G, Orofino MG, Vacca A, Piroddi A, Piras E, Addari MC, Caria R, Pilia

MP, Origa R, Moi P, La Nasa G. Long-term survival of beta thalassemia major

patients treated with hematopoietic stem cell transplantation compared with

survival with conventional treatment. Am J Hematol. 2017 Dec;92(12):1303-1310.

doi: 10.1002/ajh.24898. Epub 2017 Sep 25. PMID: 28850704.

65: Caocci G, Greco M, Arras M, Cusano R, Orrù S, Martino B, Abruzzese E,

Galimberti S, Mulas O, Trucas M, Littera R, Lai S, Carcassi C, La Nasa G. HLA-G

molecules and clinical outcome in Chronic Myeloid Leukemia. Leuk Res. 2017

Oct;61:1-5. doi: 10.1016/j.leukres.2017.08.005. Epub 2017 Aug 18. PMID:

28841441.

66: Martino B, Mammì C, Labate C, Rodi S, Ielo D, Priolo M, Postorino M, Tripepi

G, Ronco F, Laganà C, Musolino C, Greco M, La Nasa G, Caocci G. Genetic risk of

prediabetes and diabetes development in chronic myeloid leukemia patients

treated with nilotinib. Exp Hematol. 2017 Nov;55:71-75. doi:

10.1016/j.exphem.2017.07.007. Epub 2017 Jul 28. PMID: 28757432.

67: Littera R, Piredda G, Argiolas D, Lai S, Congeddu E, Ragatzu P, Melis M,

Carta E, Michittu MB, Valentini D, Cappai L, Porcella R, Alba F, Serra M, Loi V,

Maddi R, Orrù S, La Nasa G, Caocci G, Cusano R, Arras M, Frongia M, Pani A,

Carcassi C. KIR and their HLA Class I ligands: Two more pieces towards

completing the puzzle of chronic rejection and graft loss in kidney

transplantation. PLoS One. 2017 Jul 7;12(7):e0180831. doi:

10.1371/journal.pone.0180831. PMID: 28686681; PMCID: PMC5501603.

68: Sanna M, Caocci G, Orrù F, Ledda A, Vacca A, Piras E, Fozza C, Deias P,

Tidore G, Dore F, La Nasa G. Safe fluoroquinolones prophylaxis in blood cancer

patients with chemotherapy-induced neutropenia and Glucose-6-Phosphate-

Dehydrogenase deficiency. J Clin Pharm Ther. 2017 Dec;42(6):733-737. doi:

10.1111/jcpt.12571. Epub 2017 Jun 8. PMID: 28597476.

69: Caocci G, Greco M, La Nasa G. Bone Marrow Homing and Engraftment Defects of

Human Hematopoietic Stem and Progenitor Cells. Mediterr J Hematol Infect Dis.

2017 Apr 19;9(1):e2017032. doi: 10.4084/MJHID.2017.032. PMID: 28512561; PMCID:

PMC5419183.

70: Sanna M, Caocci G, Ledda A, Orrù F, Fozza C, Deias P, Tidore G, Dore F, La

Nasa G. Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal

disease in patients with acute myeloid leukemia. Leuk Lymphoma. 2017

Nov;58(11):2558-2564. doi: 10.1080/10428194.2017.1312666. Epub 2017 Apr 12.

PMID: 28402154.

71: La Nasa G, Vacca A, Littera R, Piras E, Orru S, Greco M, Carcassi C, Caocci

G. What Unrelated Hematopoietic Stem Cell Transplantation in Thalassemia Taught

us about Transplant Immunogenetics. Mediterr J Hematol Infect Dis. 2016 Oct

20;8(1):e2016048. doi: 10.4084/MJHID.2016.048. PMID: 27872728; PMCID:

PMC5111522.

72: Danjou F, Fozza C, Zoledziewska M, Mulas A, Corda G, Contini S, Dore F,

Galleu A, Di Tucci AA, Caocci G, Gaviano E, Latte G, Gabbas A, Casula P, Delogu

LG, La Nasa G, Angelucci E, Cucca F, Longinotti M. A genome-wide association

study by ImmunoChip reveals potential modifiers in myelodysplastic syndromes.

Exp Hematol. 2016 Nov;44(11):1034-1038. doi: 10.1016/j.exphem.2016.07.005. Epub

2016 Jul 21. PMID: 27449989.

73: Caocci G, Greco M, Delogu G, Secchi C, Perra A, Ghiani S, Orru F, Vacca A,

Galimi F, La Nasa G. Ruxolitinib therapy and telomere length in myelofibrosis.

Blood Cancer J. 2016 Oct 7;6(10):e479. doi: 10.1038/bcj.2016.91. PMID: 27716743;

PMCID: PMC5098263.

74: Caocci G, Vacca A, Piras E, Serreli V, Dessi C, Marcias M, Risso P, La Nasa

G. Return to normal life after hematopoietic stem cell transplantation for

thalassemia: a study of patients transplanted from matched sibling donors. Bone

Marrow Transplant. 2016 Dec;51(12):1640-1641. doi: 10.1038/bmt.2016.243. Epub

2016 Sep 19. PMID: 27643871.

75: Caocci G, Greco M, Delogu G, Secchi C, Martino B, Labate C, Abruzzese E,

Trawinska MM, Galimberti S, Orru F, Fozza C, Gambacorti Passerini C, Galimi F,

La Nasa G. Telomere length shortening is associated with treatment-free

remission in chronic myeloid leukemia patients. J Hematol Oncol. 2016 Jul

29;9(1):63. doi: 10.1186/s13045-016-0293-y. PMID: 27473052; PMCID: PMC4966800.

76: Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F,

Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Bergamaschi M, Vincelli

ID, Rodeghiero F, Ruggeri M, Scaramucci L, Rambaldi A, Cascavilla N, Forghieri

F, Petrungaro A, Ditonno P, Caocci G, Cirrincione S, Mazzucconi MG. Health-

related quality of life and burden of fatigue in patients with primary immune

thrombocytopenia by phase of disease. Am J Hematol. 2016 Oct;91(10):995-1001.

doi: 10.1002/ajh.24463. Epub 2016 Jul 14. PMID: 27351715.

77: Caocci G, Greco M, Fanni D, Senes G, Littera R, Lai S, Risso P, Carcassi C,

Faa G, La Nasa G. HLA-G expression and role in advanced-stage classical Hodgkin

lymphoma. Eur J Histochem. 2016 Apr 11;60(2):2606. doi: 10.4081/ejh.2016.2606.

PMID: 27349312; PMCID: PMC4933823.

78: Caocci G, La Nasa G, Bain BJ. Erythroblast morphology in refractory anemia

with ring sideroblasts and thrombocytosis. Am J Hematol. 2016 Oct;91(10):1056.

doi: 10.1002/ajh.24448. Epub 2016 Jul 4. PMID: 27301073.

79: La Nasa G, Greco M, Littera R, Oppi S, Celeghini I, Caria R, Lai S, Porcella

R, Martino M, Romano A, Di Raimondo F, Gallamini A, Carcassi C, Caocci G. The

favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A

haplotype in patients with advanced-stage classic Hodgkin lymphoma. J Hematol

Oncol. 2016 Mar 16;9:26. doi: 10.1186/s13045-016-0255-4. PMID: 26983546; PMCID:

PMC4793496.

80: Littera R, Chessa L, Onali S, Figorilli F, Lai S, Secci L, La Nasa G, Caocci

G, Arras M, Melis M, Cappellini S, Balestrieri C, Serra G, Conti M, Zolfino T,

Casale M, Casu S, Pasetto MC, Barca L, Salustro C, Matta L, Scioscia R, Zamboni

F, Faa G, Orrù S, Carcassi C. Exploring the Role of Killer Cell Immunoglobulin-

Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis. PLoS One.

2016 Jan 8;11(1):e0146086. doi: 10.1371/journal.pone.0146086. PMID: 26744892;

PMCID: PMC4712907.

81: Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, Caocci G,

Stauder R, Selleslag D, Sprangers M, Platzbecker U, Ricco A, Sanpaolo G, Beyne-

Rauzy O, Buccisano F, Palumbo GA, Bowen D, Nguyen K, Niscola P, Vignetti M,

Mandelli F. Prognostic value of self-reported fatigue on overall survival in

patients with myelodysplastic syndromes: a multicentre, prospective,

observational, cohort study. Lancet Oncol. 2015 Nov;16(15):1506-1514. doi:

10.1016/S1470-2045(15)00206-5. Epub 2015 Sep 21. PMID: 26404501.

82: Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F. Health-

related quality of life and symptom assessment in randomized controlled trials

of patients with leukemia and myelodysplastic syndromes: What have we learned?

Crit Rev Oncol Hematol. 2015 Dec;96(3):542-54. doi:

10.1016/j.critrevonc.2015.07.012. Epub 2015 Aug 1. PMID: 26324461.

83: Caocci G, Maccioni A, Murgia F, Perra A, Usai M, Piga M, Mascia R, La Nasa

G. Modulation of bone marrow microenvironment following ruxolitinib therapy in

myelofibrosis. Leuk Lymphoma. 2016 May;57(5):1215-8. doi:

10.3109/10428194.2015.1079320. Epub 2015 Oct 5. PMID: 26308187.

84: Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S, Ragatzu P,

Galimberti S, Baratè C, Mulas O, Labate C, Littera R, Carcassi C, Gambacorti

Passerini C, La Nasa G. Killer immunoglobulin-like receptors can predict TKI

treatment-free remission in chronic myeloid leukemia patients. Exp Hematol. 2015

Dec;43(12):1015-1018.e1. doi: 10.1016/j.exphem.2015.08.004. Epub 2015 Aug 22.

PMID: 26306453.

85: Caocci G, Voso MT, Angelucci E, Stauder R, Cottone F, Abel G, Nguyen K,

Platzbecker U, Beyne-Rauzy O, Gaidano G, Invernizzi R, Molica S, Criscuolo M,

Breccia M, Lübbert M, Sanpaolo G, Buccisano F, Ricco A, Palumbo GA, Niscola P,

Zhang H, Fenu S, La Nasa G, Mandelli F, Efficace F. Accuracy of physician

assessment of treatment preferences and health status in elderly patients with

higher-risk myelodysplastic syndromes. Leuk Res. 2015 Aug;39(8):859-65. doi:

10.1016/j.leukres.2015.05.012. Epub 2015 Jun 12. PMID: 26120100.

86: Secchi C, Carta M, Crescio C, Spano A, Arras M, Caocci G, Galimi F, La Nasa

G, Pippia P, Turrini F, Pantaleo A. T cell tyrosine phosphorylation response to

transient redox stress. Cell Signal. 2015 Apr;27(4):777-88. doi:

10.1016/j.cellsig.2014.12.014. Epub 2015 Jan 6. PMID: 25572700.

87: Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D,

Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G,

Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu

S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F. Prevalence, severity and

correlates of fatigue in newly diagnosed patients with myelodysplastic

syndromes. Br J Haematol. 2015 Feb;168(3):361-70. doi: 10.1111/bjh.13138. Epub

2014 Oct 1. PMID: 25272332.

88: Putzu L, Caocci G, Di Ruberto C. Leucocyte classification for leukaemia

detection using image processing techniques. Artif Intell Med. 2014

Nov;62(3):179-91. doi: 10.1016/j.artmed.2014.09.002. Epub 2014 Sep 16. PMID:

25241903.

89: Caocci G, Greco M, La Nasa G. Safe discontinuation of nilotinib in a patient

with chronic myeloid leukemia: a case report. J Med Case Rep. 2014 Sep 6;8:295.

doi: 10.1186/1752-1947-8-295. PMID: 25194418; PMCID: PMC4160914.

90: Pisu S, Caocci G, d'Aloja E, Efficace F, Vacca A, Piras E, Orofino MG,

Addari C, Pintor M, Demontis R, Demuru F, Pittau MR, Collins GS, La Nasa G.

Reassessing the approach to informed consent: the case of unrelated

hematopoietic stem cell transplantation in adult thalassemia patients. Philos

Ethics Humanit Med. 2014 Aug 12;9:13. doi: 10.1186/1747-5341-9-13. PMID:

25115172; PMCID: PMC4136633.

91: Romano A, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, La Nasa

G. Immunological deregulation in classic hodgkin lymphoma. Mediterr J Hematol

Infect Dis. 2014 Jun 1;6(1):e2014039. doi: 10.4084/MJHID.2014.039. PMID:

24959336; PMCID: PMC4063611.

92: Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A,

Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A,

Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A,

Fazi P, Vignetti M, Tura S. Deferasirox for transfusion-dependent patients with

myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID: 24580147.

93: Efficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G,

Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U,

Mandelli F. Preference for involvement in treatment decisions and request for

prognostic information in newly diagnosed patients with higher-risk

myelodysplastic syndromes. Ann Oncol. 2014 Feb;25(2):447-54. doi:

10.1093/annonc/mdt557. PMID: 24478321.

94: Sanna M, Caocci G, Vacca A, Piras E, Orrù F, La Nasa G. Daunorubicin,

cytarabine, and cladribine regimen plus radiotherapy and donor lymphocyte

infusion for extramedullary relapse of acute myeloid leukemia after

hematopoietic stem cell transplantation. Case Rep Hematol. 2013;2013:258028.

doi: 10.1155/2013/258028. Epub 2013 Aug 27. PMID: 24066245; PMCID: PMC3771481.

95: Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, Guilhot F,

Cocks K, Naeem A, Sprangers M, Oerlemans S, Chie W, Castagnetti F, Bombaci F,

Sharf G, Cardoni A, Noens L, Pallua S, Salvucci M, Nicolatou-Galitis O, Rosti G,

Mandelli F. International development of an EORTC questionnaire for assessing

health-related quality of life in chronic myeloid leukemia patients: the EORTC

QLQ-CML24. Qual Life Res. 2014 Apr;23(3):825-36. doi: 10.1007/s11136-013-0523-5.

Epub 2013 Sep 13. PMID: 24026634.

96: La Nasa G, Caocci G, Efficace F, Dessì C, Vacca A, Piras E, Sanna M, Marcias

M, Littera R, Carcassi C, Lucarelli G. Long-term health-related quality of life

evaluated more than 20 years after hematopoietic stem cell transplantation for

thalassemia. Blood. 2013 Sep 26;122(13):2262-70. doi:

10.1182/blood-2013-05-502658. Epub 2013 Aug 19. PMID: 23958950.

97: Greco M, Caocci G, La Nasa G. Early Complete Molecular Response to First-

Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230

Transcript. Case Rep Hematol. 2013;2013:871476. doi: 10.1155/2013/871476. Epub

2013 Jul 11. PMID: 23956893; PMCID: PMC3728508.

98: Greco M, Caocci G, Ledda A, Vacca A, Arras M, Celeghini I, La Nasa G. Early

Death in Two Patients with Acute Promyelocytic Leukemia Presenting the bcr3

Isoform, FLT3-ITD Mutation, and Elevated WT1 Level. Case Rep Hematol.

2013;2013:896394. doi: 10.1155/2013/896394. Epub 2013 Jul 7. PMID: 23936694;

PMCID: PMC3722971.

99: Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G. Reactivation of

hepatitis B virus infection following ruxolitinib treatment in a patient with

myelofibrosis. Leukemia. 2014 Jan;28(1):225-7. doi: 10.1038/leu.2013.235. Epub

2013 Aug 9. PMID: 23929216.

100: Littera R, Zamboni F, Tondolo V, Fantola G, Chessa L, Orrù N, Sanna M,

Valentini D, Cappai L, Mulargia M, Caocci G, Arras M, Floris A, Orrù S, La Nasa

G, Carcassi C. Absence of activating killer immunoglobulin-like receptor genes

combined with hepatitis C viral genotype is predictive of hepatocellular

carcinoma. Hum Immunol. 2013 Oct;74(10):1288-94. doi:

10.1016/j.humimm.2013.05.007. Epub 2013 Jun 10. PMID: 23756163.

101: Caocci G, Ledda A, Floris R, Vacca A, Arras M, Greco M, Sanna M, La Nasa G.

Successful and safe stem cell mobilization using plerixafor in a patient with

Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma.

2014 Feb;55(2):462-3. doi: 10.3109/10428194.2013.809079. Epub 2013 Jun 24. PMID:

23713454.

102: Littera R, Piredda G, Pani A, Frongia M, Onano B, Michittu MB, Murgia MG,

Lai S, Alba F, Valentini MD, Loi V, Caocci G, Orrù S, La Nasa G, Carcassi C.

Role of human leukocyte antigen-G 14-base pair polymorphism in kidney

transplantation outcomes. J Nephrol. 2013 Nov-Dec;26(6):1170-8. doi:

10.5301/jn.5000252. Epub 2013 Mar 6. PMID: 23475463.

103: La Nasa G, Caocci G, Littera R, Atzeni S, Vacca A, Mulas O, Langiu M, Greco

M, Orrù S, Orrù N, Floris A, Carcassi C. Homozygosity for killer immunoglobin-

like receptor haplotype A predicts complete molecular response to treatment with

tyrosine kinase inhibitors in chronic myeloid leukemia patients. Exp Hematol.

2013 May;41(5):424-31. doi: 10.1016/j.exphem.2013.01.008. Epub 2013 Feb 1. PMID:

23380384.

104: Piras E, Caocci G, Pisano V, Orrù F, Murgia F, Sanna M, Vacca A, La Nasa G.

Guillain-Barré syndrome after human herpesvirus-6 reactivation in unrelated

hematopoietic stem cell transplantation. Leuk Lymphoma. 2013 Jun;54(6):1332-3.

doi: 10.3109/10428194.2012.740560. Epub 2013 Mar 4. PMID: 23088724.

105: Pisu S, Demuru F, Caocci G, La Nasa G. Ethical concerns surrounding the

conception of an HLA compatible child for medical purposes. Haematologica. 2012

Sep;97(9):e33; author reply e36. doi: 10.3324/haematol.2012.068015. PMID:

22952333; PMCID: PMC3436224.

106: Caocci G, Maioli MA, Atzeni S, Piras R, Carboni N, La Nasa G. Absence of

histological myopathy in chronic myeloid leukemia patients complaining of muscle

spasms and myalgia during treatment with nilotinib. Leuk Res. 2012

Sep;36(9):e206-8. doi: 10.1016/j.leukres.2012.06.006. Epub 2012 Jun 26. PMID:

22742815.

107: Caocci G, Efficace F, Ciotti F, Roncarolo MG, Vacca A, Piras E, Littera R,

Markous RS, Collins GS, Ciceri F, Mandelli F, Marktel S, La Nasa G. Health

related quality of life in Middle Eastern children with beta-thalassemia. BMC

Blood Disord. 2012 Jun 22;12:6. doi: 10.1186/1471-2326-12-6. PMID: 22726530;

PMCID: PMC3496588.

108: Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A, Pagliara

D, Contoli B, Pinto RM, Caocci G, Mastronuzzi A, La Nasa G, Locatelli F.

Allogeneic hematopoietic stem cell transplantation in thalassemia major: results

of a reduced-toxicity conditioning regimen based on the use of treosulfan.

Blood. 2012 Jul 12;120(2):473-6. doi: 10.1182/blood-2012-04-423822. Epub 2012

May 29. PMID: 22645178.

109: Efficace F, Breccia M, Saussele S, Kossak-Roth U, Cardoni A, Caocci G, Chie

W, Naeem A, Nicolatou-Galitis O, Cocks K, Vignetti M, Baccarani M, Mandelli F,

Sprangers M. Which health-related quality of life aspects are important to

patients with chronic myeloid leukemia receiving targeted therapies and to

health care professionals? GIMEMA and EORTC Quality of Life Group. Ann Hematol.

2012 Sep;91(9):1371-81. doi: 10.1007/s00277-012-1458-6. Epub 2012 Apr 29. PMID:

22543826.

110: Orrù S, Orrù N, Manolakos E, Littera R, Caocci G, Giorgiani G, Bertaina A,

Pagliara D, Giardini C, Nesci S, Locatelli F, Carcassi C, La Nasa G. Recipient

CTLA-4*CT60-AA genotype is a prognostic factor for acute graft-versus-host

disease in hematopoietic stem cell transplantation for thalassemia. Hum Immunol.

2012 Mar;73(3):282-6. doi: 10.1016/j.humimm.2011.12.014. Epub 2011 Dec 31. PMID:

22245568; PMCID: PMC3314940.

111: Caocci G, Vacca A, Ledda A, Murgia F, Piras E, Greco M, Arras M, Atzeni S,

Littera R, La Nasa G. Prophylactic and preemptive therapy with dasatinib after

hematopoietic stem cell transplantation for Philadelphia chromosome-positive

acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2012

Apr;18(4):652-4. doi: 10.1016/j.bbmt.2011.12.587. Epub 2012 Jan 9. PMID:

22240733.

112: Littera R, Orrù N, Caocci G, Sanna M, Mulargia M, Piras E, Vacca A,

Giardini C, Orofino MG, Visani G, Bertaina A, Giorgiani G, Locatelli F, Carcassi

C, La Nasa G. Interactions between killer immunoglobulin-like receptors and

their human leucocyte antigen Class I ligands influence the outcome of unrelated

haematopoietic stem cell transplantation for thalassaemia: a novel predictive

algorithm. Br J Haematol. 2012 Jan;156(1):118-28. doi:

10.1111/j.1365-2141.2011.08923.x. Epub 2011 Nov 14. PMID: 22077388.

113: Caocci G, La Nasa G, d'Aloja E, Vacca A, Piras E, Pintor M, Demontis R,

Pisu S. Ethical issues of unrelated hematopoietic stem cell transplantation in

adult thalassemia patients. BMC Med Ethics. 2011 Mar 8;12:4. doi:

10.1186/1472-6939-12-4. PMID: 21385429; PMCID: PMC3063251.

114: Caocci G, Efficace F, Ciotti F, Roncarolo MG, Vacca A, Piras E, Littera R,

Dawood Markous RS, Collins GS, Ciceri F, Mandelli F, Marktel S, La Nasa G.

Prospective assessment of health-related quality of life in pediatric patients

with beta-thalassemia following hematopoietic stem cell transplantation. Biol

Blood Marrow Transplant. 2011 Jun;17(6):861-6. doi: 10.1016/j.bbmt.2010.09.011.

Epub 2010 Sep 24. PMID: 20870029.

115: Baccoli A, Manconi AR, Caocci G, Pisu S. Isolated jejunal perforation after

blunt trauma. Report of three cases. G Chir. 2010 Apr;31(4):167-70. PMID:

20444335.

116: Caocci G, Baccoli R, Vacca A, Mastronuzzi A, Bertaina A, Piras E, Littera

R, Locatelli F, Carcassi C, La Nasa G. Comparison between an artificial neural

network and logistic regression in predicting acute graft-vs-host disease after

unrelated donor hematopoietic stem cell transplantation in thalassemia patients.

Exp Hematol. 2010 May;38(5):426-33. doi: 10.1016/j.exphem.2010.02.012. Epub 2010

Mar 4. PMID: 20206661.

117: Littera R, Orrù N, Vacca A, Bertaina A, Caocci G, Mulargia M, Giardini C,

Piras E, Mastronuzzi A, Vinti L, Orrù S, Locatelli F, Carcassi C, La Nasa G. The

role of killer immunoglobulin-like receptor haplotypes on the outcome of

unrelated donor haematopoietic SCT for thalassaemia. Bone Marrow Transplant.

2010 Nov;45(11):1618-24. doi: 10.1038/bmt.2010.24. Epub 2010 Feb 22. PMID:

20173792.

118: Caocci G, Atzeni S, Orrù N, Littera R, Culurgioni F, Marongiu F, La Nasa G.

Response to imatinib in a patient with chronic myeloid leukemia simultaneously

expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation. Leuk Res. 2010

Jan;34(1):e27-9. doi: 10.1016/j.leukres.2009.08.009. Epub 2009 Sep 12. PMID:

19748671.

119: Tuveri M, Caocci G, Efficace F, Medas F, Collins GS, Pisu S. Different

perception of surgical risks between physicians and patients undergoing

laparoscopic cholecystectomy. Surg Laparosc Endosc Percutan Tech. 2009

Aug;19(4):305-11. doi: 10.1097/SLE.0b013e3181a8295e. PMID: 19692878.

120: Caocci G, Atzeni S, Vacca A, Orrù N, Ledda A, La Nasa G. Familial

occurrence of chronic myeloid leukemia. Leuk Lymphoma. 2009 May;50(5):854-6.

doi: 10.1080/10428190902842634. PMID: 19452324.

121: Caocci G, La Nasa G, Efficace F. Health-related quality of life and symptom

assessment in patients with myelodysplastic syndromes. Expert Rev Hematol. 2009

Feb;2(1):69-80. doi: 10.1586/17474086.2.1.69. PMID: 21082996.

122: Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C, Caocci G,

Comoli P, Mastronuzzi A, Merli P, La Nasa G, Locatelli F. Treosulfan-based

conditioning regimen for allogeneic haematopoietic stem cell transplantation in

patients with thalassaemia major. Br J Haematol. 2008 Nov;143(4):548-51. doi:

10.1111/j.1365-2141.2008.07385.x. PMID: 18986389.

123: Caocci G, Pisu S, La Nasa G. A simulated case of chronic myeloid leukemia:

the growing risk of Munchausen's syndrome by internet. Leuk Lymphoma. 2008

Sep;49(9):1826-8. doi: 10.1080/10428190802179889. PMID: 18608864.

124: Di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, Caocci G,

Agus A, Angelucci E. Myocardial iron overload assessment by T2* magnetic

resonance imaging in adult transfusion dependent patients with acquired anemias.

Haematologica. 2008 Sep;93(9):1385-8. doi: 10.3324/haematol.12759. Epub 2008 Jul

4. PMID: 18603557.

125: Caocci G, Atzeni S, Orrù N, Azzena L, Martorana L, Littera R, Ledda A, La

Nasa G. Gynecomastia in a male after dasatinib treatment for chronic myeloid

leukemia. Leukemia. 2008 Nov;22(11):2127-8. doi: 10.1038/leu.2008.106. Epub 2008

May 8. PMID: 18463676.

126: La Nasa G, Littera R, Locatelli F, Giardini C, Ventrella A, Mulargia M,

Vacca A, Orrù N, Orrù S, Piras E, Giustolisi G, Lisini D, Nesci S, Caocci G,

Carcassi C. Status of donor-recipient HLA class I ligands and not the KIR

genotype is predictive for the outcome of unrelated hematopoietic stem cell

transplantation in beta-thalassemia patients. Biol Blood Marrow Transplant. 2007

Nov;13(11):1358-68. doi: 10.1016/j.bbmt.2007.07.011. Epub 2007 Sep 14. PMID:

17950922.

127: Littera R, Arras M, Ledda A, Caocci G, Tronci MB, Carcassi C, La Nasa G.

Long-term efficacy and tolerance of rituximab for post-transfusional alloimmune

haemolytic anaemia in a thalassaemia patient. Br J Haematol. 2008

Jan;140(1):114-5. doi: 10.1111/j.1365-2141.2007.06858.x. Epub 2007 Oct 3. PMID:

17916104.

128: La Nasa G, Littera R, Locatelli F, Lai S, Alba F, Caocci G, Lisini D, Nesci

S, Vacca A, Piras E, Bernardo ME, Di Cesare-Merlone A, Orrù S, Carcassi C. The

human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-

host disease in unrelated bone marrow transplantation for thalassaemia. Br J

Haematol. 2007 Oct;139(2):284-8. doi: 10.1111/j.1365-2141.2007.06779.x. PMID:

17897304.

129: Caocci G, Pisu S. Overcoming scientific barriers and human prudence. Bone

Marrow Transplant. 2006 Dec;38(12):829-30; author reply 830. doi:

10.1038/sj.bmt.1705536. PMID: 17133241.

130: Ledda A, Caocci G, Spinicci G, Cocco E, Mamusa E, La Nasa G. Two new cases

of acute promyelocytic leukemia following mitoxantrone treatment in patients

with multiple sclerosis. Leukemia. 2006 Dec;20(12):2217-8. doi:

10.1038/sj.leu.2404443. Epub 2006 Oct 19. PMID: 17051242.

131: Caocci G, Baccoli R, Ledda A, Littera R, La Nasa G. A mathematical model

for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic

patients affected by myelodysplastic syndromes: correlation with quality of life

and fatigue. Leuk Res. 2007 Feb;31(2):249-52. doi:

10.1016/j.leukres.2006.05.015. Epub 2006 Jun 30. PMID: 16814382.

132: La Nasa G, Argiolu F, Giardini C, Pession A, Fagioli F, Caocci G, Vacca A,

De Stefano P, Piras E, Ledda A, Piroddi A, Littera R, Nesci S, Locatelli F.

Unrelated bone marrow transplantation for beta-thalassemia patients: The

experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci.

2005;1054:186-95. doi: 10.1196/annals.1345.023. PMID: 16339665.

133: Caocci G, Pisu S, Argiolu F, Giardini C, Locatelli F, Vacca A, Orofino MG,

Piras E, De Stefano P, Addari MC, Ledda A, La Nasa G. Decision-making in adult

thalassemia patients undergoing unrelated bone marrow transplantation: quality

of life, communication and ethical issues. Bone Marrow Transplant. 2006

Jan;37(2):165-9. doi: 10.1038/sj.bmt.1705236. PMID: 16299541.

134: Caocci G, Fenu L, La Nasa G, Marongiu F. Superior sagittal sinus thrombosis

after lumbar puncture in a patient with T-cell lymphoblastic lymphoma: role of

the prothrombin G20210A mutation and 4G/4G genotype. Thromb Haemost. 2005

Oct;94(4):881-2. PMID: 16270647.

135: La Nasa G, Caocci G, Argiolu F, Giardini C, Locatelli F, Vacca A, Orofino

MG, Piras E, Addari MC, Ledda A, Contu L. Unrelated donor stem cell

transplantation in adult patients with thalassemia. Bone Marrow Transplant. 2005

Dec;36(11):971-5. doi: 10.1038/sj.bmt.1705173. PMID: 16205730.

136: La Nasa G, Giardini C, Locatelli F, Argiolu F, Vassallo E, Prete A, Caocci

G, Floris R, Garau P, Littera R, Mantovani D, Oppi S, Piras E, De Stefano P,

Sanna MA, Mulargia M, Carcassi C, Contu L; Italian Bone Marrow Transplant Group

(GITMO). Unrelated bone marrow transplantation in thalassemia. The experience of

the Italian Bone Marrow Transplant Group (GITMO). Haematologica. 2002 Aug;87(8

Suppl):58-61. PMID: 12412392.

Prof Caocci has published more than 200 abstracts

Questionnaire and social

Share on: